These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 15917769)

  • 21. Improving influenza vaccines.
    Sambhara S; Rappuoli R
    Expert Rev Vaccines; 2012 Aug; 11(8):871-2. PubMed ID: 23002964
    [No Abstract]   [Full Text] [Related]  

  • 22. Strategies for developing vaccines against H5N1 influenza A viruses.
    Horimoto T; Kawaoka Y
    Trends Mol Med; 2006 Nov; 12(11):506-14. PubMed ID: 17011235
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Statement on influenza vaccination for the 1991-92 season.
    CMAJ; 1991 Sep; 145(5):465-9. PubMed ID: 1878828
    [No Abstract]   [Full Text] [Related]  

  • 24. Flu jabs urged for developing countries.
    Abbott A
    Nature; 2009 Jul; 460(7252):156-7. PubMed ID: 19587728
    [No Abstract]   [Full Text] [Related]  

  • 25. Potency of an inactivated avian influenza vaccine prepared from a non-pathogenic H5N1 reassortant virus generated between isolates from migratory ducks in Asia.
    Isoda N; Sakoda Y; Kishida N; Soda K; Sakabe S; Sakamoto R; Imamura T; Sakaguchi M; Sasaki T; Kokumai N; Ohgitani T; Saijo K; Sawata A; Hagiwara J; Lin Z; Kida H
    Arch Virol; 2008; 153(9):1685-92. PubMed ID: 18651092
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Getting ready for another flu season.
    Bren L
    FDA Consum; 2006; 40(4):8-9. PubMed ID: 17243281
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Viruses of mass destruction.
    Barry JM
    Fortune; 2004 Nov; 150(9):74, 76. PubMed ID: 15543821
    [No Abstract]   [Full Text] [Related]  

  • 28. Vaccine-preventable influenza disease burden from clinical trials of Vaxigrip - an inactivated split virion influenza vaccine - supports wider vaccine use.
    Arnoux S; Weinberger C; Gessner BD
    Vaccine; 2007 Nov; 25(45):7720-31. PubMed ID: 17920168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Generation and evaluation of reassortant influenza vaccines made by reverse genetics for H9N2 avian influenza in Korea.
    Song JM; Lee YJ; Jeong OM; Kang HM; Kim HR; Kwon JH; Kim JH; Seong BL; Kim YJ
    Vet Microbiol; 2008 Aug; 130(3-4):268-76. PubMed ID: 18374520
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessing vaccine efficacy in influenza clinical trials: challenges and difficulties.
    Dewe W; Benoit A; Legrand C
    Expert Rev Clin Pharmacol; 2013 Jul; 6(4):403-11. PubMed ID: 23927668
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Flu-vaccine makers toil to boost supply.
    Dennis C
    Nature; 2006 Apr; 440(7088):1099. PubMed ID: 16641963
    [No Abstract]   [Full Text] [Related]  

  • 32. Production technologies change flu vaccine landscape.
    Sheridan C
    Nat Biotechnol; 2007 Jul; 25(7):701. PubMed ID: 17621280
    [No Abstract]   [Full Text] [Related]  

  • 33. Public health. Rethinking influenza.
    Rappuoli R; Del Giudice G; Nabel GJ; Osterhaus AD; Robinson R; Salisbury D; Stöhr K; Treanor JJ
    Science; 2009 Oct; 326(5949):50. PubMed ID: 19797644
    [No Abstract]   [Full Text] [Related]  

  • 34. A one-size-fits-all flu vaccine?
    Kaiser J
    Science; 2006 Apr; 312(5772):380-2. PubMed ID: 16627732
    [No Abstract]   [Full Text] [Related]  

  • 35. Should vaccines and antiviral therapy for influenza now be deployed strategically?
    Griffiths PD
    Rev Med Virol; 2004; 14(3):137-9. PubMed ID: 15124230
    [No Abstract]   [Full Text] [Related]  

  • 36. Cell culture–derived influenza vaccines: has their time come?
    Bernstein DI
    Clin Infect Dis; 2010 Nov; 51(9):1005-6. PubMed ID: 20868285
    [No Abstract]   [Full Text] [Related]  

  • 37. How to flee the flu.
    Junker AK; Bonilla FA; Sullivan KE
    Clin Immunol; 2004 Sep; 112(3):219-20. PubMed ID: 15308112
    [No Abstract]   [Full Text] [Related]  

  • 38. MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development?
    O'Hagan DT; Wack A; Podda A
    Clin Pharmacol Ther; 2007 Dec; 82(6):740-4. PubMed ID: 17971820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influenza viruses: an introduction.
    Kawaoka Y; Neumann G
    Methods Mol Biol; 2012; 865():1-9. PubMed ID: 22528150
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential.
    Desheva JA; Lu XH; Rekstin AR; Rudenko LG; Swayne DE; Cox NJ; Katz JM; Klimov AI
    Vaccine; 2006 Nov; 24(47-48):6859-66. PubMed ID: 17050041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.